NSE - Delayed Quote INR
SMS Pharmaceuticals Limited (SMSPHARMA.NS)
240.35
-1.72
(-0.71%)
At close: April 25 at 3:30:01 PM GMT+5:30
Breakdown
TTM
3/31/2024
3/31/2023
3/31/2022
3/31/2021
Total Revenue
7,775,440
7,064,565
5,197,468
5,150,158
5,608,173
Cost of Revenue
5,326,368
4,977,079
3,906,077
3,335,860
3,793,921
Gross Profit
2,449,072
2,087,486
1,291,391
1,814,298
1,814,252
Operating Expense
1,465,735
1,235,004
1,066,577
989,608
825,617
Operating Income
983,337
852,482
224,814
824,690
988,635
Net Non Operating Interest Income Expense
-184,661
-228,378
-211,994
-186,043
-108,742
Pretax Income
855,503
661,068
53,491
684,991
911,198
Tax Provision
221,825
169,068
14,650
6,182
301,552
Net Income Common Stockholders
660,991
498,260
-70,593
622,199
625,269
Diluted NI Available to Com Stockholders
660,991
498,260
-70,593
622,199
625,269
Basic EPS
7.82
5.89
-0.83
7.35
7.39
Diluted EPS
7.82
5.89
-0.83
7.35
7.39
Basic Average Shares
84,541.24
84,652
84,652
84,652
84,652
Diluted Average Shares
84,541.24
84,652
84,652
84,652
84,652
Rent Expense Supplemental
--
717
804
939
1,043
Total Expenses
6,792,103
6,212,083
4,972,654
4,325,468
4,619,538
Net Income from Continuing & Discontinued Operation
660,991
498,260
-70,593
622,199
625,269
Normalized Income
660,715.46
497,983.14
-70,197.99
622,235.67
625,322.52
Interest Income
--
7,579
7,748
5,596
3,144
Interest Expense
182,460
226,177
209,944
181,566
102,536
Net Interest Income
-184,661
-228,378
-211,994
-186,043
-108,742
EBIT
1,037,963
887,245
263,435
866,557
1,013,734
EBITDA
1,374,100
1,202,402
584,689
1,188,082
1,236,550
Reconciled Cost of Revenue
5,326,368
4,977,079
3,906,077
3,335,860
3,793,921
Reconciled Depreciation
336,137
315,157
321,254
321,525
222,816
Net Income from Continuing Operation Net Minority Interest
660,991
498,260
-70,593
622,199
625,269
Total Unusual Items Excluding Goodwill
372
372
-544
-37
-80
Total Unusual Items
372
372
-544
-37
-80
Normalized EBITDA
1,373,728
1,202,030
585,233
1,188,119
1,236,630
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
96.46
95.14
-148.99
-0.33
-26.48
3/31/2021 - 2/28/2007
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
Upgrade